Is Brainstorm Cell Therapeutics Inc. (BCLI) a Buy, Sell, or Hold?
OTC : BCLI
Brainstorm Cell Therapeutics Inc.
$0.79 USD
$0.0 (0.31%)
- Volume
- 5.38K
- Average Volume
- 16.89K
- Market Capitalization
- $8.72M
- P/E Ratio
- -0.84
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.69
- Year Low
- $0.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.02
Company Overview
OTC
Chaim Lebovits
Biotechnology
Healthcare
BCLI
19
US
USD
Liquidity Metrics
-0.14
0.02
0.02
0.00
0.00
Sales & Valuation
-$
0.00
-0.79
-1.31
-0.60
Profitability
-$1.11
-$10.31M
0.00%
0.00%
109.21%
-1676.01%
P/E Metrics
-0.84
-0.01
-0.01
Analyst Price Target & Rating
2/5
3 Analysts
%
Financial Health Scores
-661.55
1/9
-$11.58M
$571K
$11.76M
-$8.91M
Key Metrics (TTM)
$10.19M
0.00
-1.17
0.02
109.21%
91.81%
-109.78%
-76.44%
-31420 days
Company Executives
| Name | Title |
|---|---|
| Peter J. Pitts | Chief Strategic Regulatory and Policy Officer & Executive Chairman |
| Ibrahim Dagher | Executive Vice President & Chief Medical Officer |
| Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director |
| Chaim Lebovits | President & Chief Executive Officer |
| Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs |
| Hartoun Hartounian | Executive Vice President & Chief Operating Officer |
| Netta Blondheim-Shraga | Senior Vice President of Research and Development |
| Alla Patlis | Interim Chief Financial Officer & Controller |
Poll Results
No votes yet today — be the first to share your view!
About Brainstorm Cell Therapeutics Inc. (OTC:BCLI) Stock
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical ... trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
2026-07-28 08:00:00
Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team.
2026-06-02 09:00:00
Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine NEW YORK, June 2, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science. As the ALS community marks Lou Gehrig Day and reflects on the courage and resilience of those living with the disease, the publication highlights the growing need for regulatory approaches that keep pace with advances in science and the urgent realities faced by patients and families.
2026-05-28 07:45:00
Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, May 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter J. Pitts has been appointed to the Company's Board of Directors, effective immediately.
2026-05-19 08:00:00
$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial NEW YORK, May 19, 2026 /PRNewswire/ -- May 19, 2026 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that in May it entered into definitive agreements for a private placement yielding gross proceeds of $400,000. Transaction Highlights and Premium Pricing: The transactions were priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69.
2026-05-15 16:05:00
NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update. "The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS," said Chaim Lebovits, President and CEO.
Frequently Asked Questions
-
What is the current Brainstorm Cell Therapeutics Inc. (BCLI) stock price?
-
Brainstorm Cell Therapeutics Inc.(OTC:BCLI) stock price is $0.79 in the last trading session. During the trading session, BCLI stock reached the peak price of $1.69 while $0.46 was the lowest point it dropped to. The percentage change in BCLI stock occurred in the recent session was 0.31% while the dollar amount for the price change in BCLI stock was $0.0.
-
BCLI's industry and sector of operation?
-
The OTC listed BCLI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCLI?
-
Peter J. Pitts | Chief Strategic Regulatory and Policy Officer & Executive Chairman
Ibrahim Dagher | Executive Vice President & Chief Medical Officer
Uri Yablonka | Executive Vice President, Chief Business Officer, Secretary & Director
Chaim Lebovits | President & Chief Executive Officer
Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs -
How many employees does BCLI have?
-
Number of BCLI employees currently stands at 19. BCLI operates from 1325 Avenue of Americas, New York City, NY 10019, US.
-
Link for BCLI official website?
-
Official Website of BCLI is: https://www.brainstorm-cell.com
-
How do I contact BCLI?
-
BCLI could be contacted at phone #201 488 0460 and can also be accessed through its website. BCLI operates from 1325 Avenue of Americas, New York City, NY 10019, US.
-
How many shares of BCLI are traded daily?
-
The average number of BCLI shares traded daily for last 3 months was 16.89K.
-
What is the market cap of BCLI currently?
-
The market value of BCLI currently stands at $8.72M with its latest stock price at $0.79